Edaravone in the Treatment of Aquaporin-4 Antibody-positive Optic Neuritis
- Registration Number
- NCT05540262
- Lead Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Brief Summary
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
- Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis
- Patients with a first episode of optic neuritis in either eye
- First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone
Read More
Exclusion Criteria
- Myopia over 6 diopters
- Refractive media opacity affecting assessment of retinal layers and/or visual acuity
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Edaravone Edaravone -
- Primary Outcome Measures
Name Time Method Best-corrected visual acuity 18 months Best-corrected visual acuity will be measured by "Illiterate E"chart.
- Secondary Outcome Measures
Name Time Method Ganglion cell-inner plexiform layer 18 months Ganglion cell-inner plexiform layer will be measured by optical coherence tomography.
Peripapillary retinal nerve fiber layer 18 months Peripapillary retinal nerve fiber layer will be measured by optical coherence tomography.
Trial Locations
- Locations (1)
Yi Du
🇨🇳Nanning, China